# US 2024/0002952 A1 · Method for in vitro diagnosis of mucositis in cancer patients undergoing antitumor therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002952 A1
- Document ID: US20240002952A1
- Status: Published application
- Kind: A1
- Application number: 18/267,743
- Filed: 2021-12-14
- Published: 2024-01-04
- Earliest claimed: 2020-12-15
- Applicants: Istituti Fisioterapici Ospitalieri
- Inventors: Sabrina STRANO; Aldo MORRONE; Claudio PULITO; Giovanni BLANDINO; Andrea SACCONI
- Web page: https://patentgrep.com/patent/US20240002952A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

A method is for in vitro diagnosis of mucositis, especially, early-stage mucositis, in cancer patients undergoing antitumor therapy, through the Measurement of microRNA expression. The diagnosed cancer patients can be treated by administering a treatment indicated in guidelines provided by Multinational Association of Supportive Care in Cancer and International Society for Oral Oncology (MASCC/ISOO), by increasing interval time before a subsequent antitumor therapy is administered, or by varying dosage of the antitumor therapy.

## Claims

### Claim 1

A method for in vitro diagnosis and treatment of mucositis in a cancer patient undergoing antitumor therapy, comprising:
obtaining a measurement, in at least one biological sample of liquid biopsy taken before the antitumor therapy and in at least one biological sample of liquid biopsy taken after the antitumor therapy, the expression of an miRNA selected from the group consisting of hsa-miR-18b-3p, hsa-miR-494-3p, hsa-miR-1202, hsa-miR-3135b, hsa-miR-6769b-5p and hsa-miR-6875-5p;
identifying a change in the expression of said miRNAs in said at least one biological sample taken after the antitumor therapy compared to the expression of said miRNAs in said at least one biological sample taken before the antitumor therapy wherein a change indicates mucositis; and
carrying out at least one of (a), (b), or (c);
(a) administering a treatment indicated in guidelines provided by Multinational Association of Supportive Core in Cancer and International Society for Oral Oncology (MASCC/ISOO);
(b) increasing interval time before a subsequent antitumor therapy is administered; or
(c) varying dosage of the antitumor therapy.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the mucositis is at a pathogenetic stage of initiation of tissue damage.

### Claim 3 (depends on 1)

The method according to claim 1, wherein one, more than one or all of the miRNAs comprise of hsa-miR-18b-3p.

### Claim 4 (depends on 3)

The method according to claim 3, wherein a step of measuring the expression of one, more than one or all said miRNAs is carried out only in at least one biological sample taken after the antitumour therapy, when the one, more than one or all of the miRNAs consist of hsa-miR-18b-3p.

### Claim 5 (depends on 1)

The method according to claim 1, wherein expression of more than one of the miRNAs is measured and wherein said more than one of the miRNAs are selected from the group consisting of hsa-miR-18b-3p and hsa-miR-494-3p; hsa-miR-18b-3p and hsa-miR-1202; hsa-miR-18b-3p and hsa-miR-3135b; hsa-miR-18b-3p and hsa-miR-6769b-5p, hsa-miR-18b-3p and hsa-miR-6875-5p, hsa-miR-494-3p and hsa-miR-1202; hsa-miR-494-3p and hsa-miR-3135b; hsa-miR-494-3p and hsa-miR-6769b-5p; hsa-miR-494-3p and hsa-miR-6875-5p; hsa-miR-1202 and hsa-miR-3135b; hsa-miR-1202 and hsa-miR-6769b-5p; hsa-miR-1202 and hsa-miR-6875-5p; hsa-miR-3135b and hsa-miR-6769b-5p; hsa-miR-3135b and hsa-miR-6875-5p; hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR-18b-3p, hsa-miR-494-3p and hsa-miR-1202; hsa-miR-18b-3p, hsa-miR-494-3p and hsa-miR-3135b, hsa-miR-18b-3p, hsa-miR-494-3p and hsa-miR-6769b-5p; hsa-miR-18b-3p, hsa-miR-494-3p and hsa-miR-6875-5p; hsa-miR-18b-3p, hsa-miR-1202 and hsa-miR-3135b, hsa-miR-18b-3p, hsa-miR-1202 and hsa-miR-6769b-5p; hsa-miR-18b-3p, hsa-miR-1202 and hsa-miR-6875-5p; hsa-miR-18b-3p, hsa-miR-3135b and hsa-miR-6769b-5p; hsa-miR-18b-3p, hsa-miR-3135b and hsa-miR-6875-5p; hsa-miR-18b-3p, hsa-miR-676911-5p and hsa-miR-6875-5p; hsa-miR-494-3p, hsa-miR-1202 and hsa-miR-3135b; miR-494-3p, hsa-miR-1202 and hsa-miR-6769b-5p; miR-494-3p, hsa-miR-1202 and hsa-miR-6875-5p; miR-494-3p, hsa-miR-3135b and hsa-miR-6769b-5p, miR-494-3p, hsa-miR-3135b and hsa-miR-6875-5p; hsa-miR-494-3p, hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR-1202, hsa-miR-3135b and hsa-miR-6769b-5p; hsa-miR-1202, hsa-miR-3135b and hsa-miR-6875-5p; hsa-miR-1202, hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR-3135b, hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR-18b-3p, hsa-miR-494-3p, hsa-miR-1202 and hsa-miR-3135b; hsa-miR-18b-3p, hsa-miR-494-3p, hsa-miR-1202 and hsa-miR-6769b-5p; hsa-miR-18b-3p, hsa-miR-494-3p, hsa-miR-1202 and hsa-miR-6875-5p; hsa-miR-18b-3p, hsa-miR-494-3p, miR-3135b and hsa-miR-676911-5p; hsa-miR-18b-3p, miR-494-3p, miR-3135b and hsa-miR-6875-5p; hsa-miR-18b-3p, miR-494-3p, hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR-18b-3p, hsa-miR-1202, miR-3135b and hsa-miR-676911-5p; hsa-miR-18b-3p, hsa-miR-1202, miR-31350 and hsa-miR-6875-5p; hsa-miR-18b-3p, hsa-miR-1202, hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR-18b-3p, miR-3135b, hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR-494-3p, hsa-miR-1202, hsa-miR-3135b and hsa-miR-6769b-5p; hsa-miR-494-3p, hsa-miR-1202, hsa-miR-3135b and hsa-miR-6875-5p, hsa-miR-494-3p, hsa-miR-1202, hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR-494-3p, hsa-miR-3135b, hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR-1202, hsa-miR-3135b, hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR-18b-3p, hsa-miR-494-3p, hsa-miR-1202, hsa-miR-3135b and hsa-miR-6769b-5p; hsa-miR-18b-3p, hsa-miR-494-3p, hsa-miR-1202, hsa-miR-31.35b and hsa-miR-6875-5p; hsa-miR-18b-3p, hsa-miR-494-3p, hsa-miR-1202, hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR-181-3p, hsa-miR-494-3p, hsa-miR-3135b, hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR-18b-3p, hsa-miR-1202, hsa-miR-3135b, hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR-494-3p, hsa-miR-1202, hsa-miR-3135b, hsa-miR-6769b-5p and hsa-miR-6875-5p; and hsa-miR-18b-3p, hsa-miR-494-3p, hsa-miR-1202, hsa-miR-3135b, hsa-miR-6769b-5p and hsa-miR-6875-5p.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the biological sample of liquid biopsy is selected from the group consisting of saliva, blood, plasma, serum, preferably saliva.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the antitumor therapy is selected from the group consisting of chemotherapy, radiotherapy and/or therapy with molecularly targeted drugs.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the chemotherapy or therapy with molecularly targeted drugs is selected from the group consisting of a PI3Kα inhibitor such as, for example, alpelisib, an alkylating agent such as, for example, cisplatin, oxaliplatin or ifosfamide, an antimetabolite such as, for example, 5-fluorouracile, capecitabin or azacytidine, an antimitotic such as, for example, paclitaxel, docetaxel or vinorelbine, an antitumour antibiotic such as, for example, doxorubicin, a topoisomerase I inhibitor such as, for example, irinotecan, ail EGFR inhibitor such as, for example, cetuximab, ail EGFR-TK inhibitor such as, for example, erlotinib, an mTOR inhibitor such as, for example, everolimus.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the method is carried out by Real-Time PCR, Microarray or RNA Next Generation Sequencing.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the antitumor therapy is against a tumor selected from the group consisting of solid tumours, such as, for example, head and neck cancer, or non-solid tumours, such as lymphoma or leukaemia.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the mucositis is a mucositis of the oropharyngeal cavity, such as, oral mucositis.

### Claim at position 12

12-19. (canceled)

### Claim 20

A kit for in vitro diagnosis of mucositis in a cancer patient undergoing antitumor therapy, said kit comprising:
one or more primer pairs and/or one or more probes complementary to more than one microRNA, said more than one microRNA being selected from the group consisting of hsa-miR-18b-3p and hsa-miR-494-3p; hsa-miR-18b-3p and hsa-miR-1202; hsa-miR-18b-3p and hsa-miR-3135b; hsa-miR-18b-3p and hsa-miR-6769b-5p; hsa-miR-18b-3p and hsa-miR-6875-5p; hsa-miR-494-3p and hsa-miR-1202; hsa-miR-494-3p and hsa-miR-3135b; hsa-miR-494-3p and hsa-miR-6769b-5p; hsa-miR-494-3p and hsa-miR-6875-5p; hsa-miR-1202 and hsa-miR-3135b; hsa-miR-1202 and hsa-miR-6769b-5p; hsa-miR-1202 and hsa-miR-6875-5p; hsa-miR-3135b and hsa-miR-6769b-5p; hsa-miR-3135b and hsa-miR-6875-5p; hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR-18b-3p, hsa-miR-494-3p and hsa-miR-1202; hsa-miR-18b-3p, hsa-miR-494-3p and hsa-miR-3135b; hsa-miR-18b-3p, hsa-miR-494-3p and hsa-miR-6769b-5p; hsa-miR-18b-3p, hsa-miR-494-3p and hsa-miR-6875-5p; hsa-miR-18b-3p, hsa-miR-1202 and hsa-miR-3135b; hsa-miR-18b-3p, hsa-miR-1202 and hsa-miR-6769b-5p; hsa-miR-18b-3p, hsa-miR-1202 and hsa-miR-6875-5p; hsa-miR-18b-3p, hsa-miR-3135b and hsa-miR-6769b-5p; hsa-miR-18b-3p, hsa-miR-3135b and hsa-miR-6875-5p; hsa-miR-18b-3p, hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR-494-3p, hsa-miR-1202 and hsa-miR-3135b; miR-494-3p, hsa-miR-1202 and hsa-miR-6769b-5p; miR-494-3p, hsa-miR-1202 and hsa-miR-6875-5p; miR-494-3p, hsa-miR-3135b and hsa-miR-6769b-5p; miR-494-3p, hsa-miR-3135b and hsa-miR-6875-5p; hsa-miR-494-3p, hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR-1202, hsa-miR-3135b and hsa-miR-6769b-5p; hsa-miR-1202, hsa-miR-3135b and hsa-miR-6875-5p; hsa-miR-1202, hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR-3135b, hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR-18b-3p, hsa-miR-494-3p, hsa-miR-1202 and hsa-miR-3135b: hsa-miR-18b-3p, hsa-miR-494-3p, hsa-miR-1202 and hsa-miR-6769b-5p; hsa-miR-18b-3p, hsa-miR-494-3p, hsa-miR-1202 and hsa-miR-6875-5p; hsa-miR-18b-3p, hsa-miR-494-3p, miR-3135b and hsa-miR-6769b-5p; hsa-miR-18b-3p, miR-494-3p, miR-3135b and hsa-miR-6875-5p; hsa-miR-18b-3p, miR-494-3p, hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR-18b-3p, hsa-miR-1202, miR-3135b and hsa-miR-6769b-5p; hsa-miR-18b-3p, hsa-miR-1202, miR-3135b and hsa-miR-6875-5p; hsa-miR-18b-3p, hsa-miR-1202, hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR-18b-3p, miR-3135b, hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR-494-3p, hsa-miR-1202, hsa-miR-3135b and hsa-miR-6769b-5p; hsa-miR-494-3p, hsa-miR-1202, hsa-miR-3135b and hsa-miR-6875-5p; hsa-miR-494-3p, hsa-miR-1202, hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR-494-3p, hsa-miR-3135b, hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR-1202, hsa-miR-3135b, hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR-18b-3p, hsa-miR-494-3p, hsa-miR-1202, hsa-miR-3135b and hsa-miR-6769b-5p; hsa-miR-18b-3p, hsa-miR-494-3p, hsa-miR-1202, hsa-miR-3135b and hsa-miR-6875-5 hsa-miR-18b-3p, hsa-miR-494-3p, hsa-miR-1202, hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR-18b-3p, hsa-miR-494-3p, hsa-miR-3135b, hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR-18b-3p, hsa-miR-1202, hsa-miR-3135b, hsa-miR-6769b-5p and hsa-miR-6875-5p; hsa-miR 494-3p, hsa-miR-1202, hsa-miR-3135b, hsa-miR-6769b-5p and hsa-miR-6875-5p; and hsa-miR-18b-3p, hsa-miR-494-3p, hsa-miR-1202, hsa-miR-3135b, hsa-miR-6769b-5p and hsa-miR-6875-5p, wherein said primers and/or probes include a detectable label;
and reagents for measuring the amount of said detectable label.

### Claim 21

A method for treatment of a tumor in a cancer patient, comprising:
obtaining a measurement, in at least one biological sample of liquid biopsy from the cancer patient, the expression of an miRNA selected from the group consisting of hsa-miR-18b-3p, hsa-miR-494-3p, hsa-miR-1202, hsa-miR-3135b, hsa-miR-6769b-5p and hsa-miR-6875-5p;
subjecting the cancer patient to antitumor therapy selected from the group consisting of chemotherapy, radiotherapy and therapy with molecularly—targeted drugs;
obtaining a measurement, in at least one biological sample of liquid biopsy from the cancer patient after the antitumor therapy, the expression of the miRNA; and
determining whether a change has occurred in the expression of said miRNAs in said at least one biological sample taken after the antitumor therapy compared to the expression of said miRNAs in said at least one biological sample taken before the antitumor therapy.

### Claim 22 (depends on 21)

The method of claim 21, wherein the antitumor therapy is selected from the group consisting of administering to the cancer patient a chemotherapy or drug selected from the group consisting of PI3Kα inhibitor, an alkylating agent, an antimetabolite, an antimitotic, an antitumour antibiotic, a topoisomerase I inhibitor, an EGFR inhibitor, an EGFR-TK inhibitor, and an mTOR inhibitor.

### Claim 23 (depends on 22)

The method of claim 22, wherein the antitumor therapy is selected from the group consisting of administering a chemotherapy or drug selected from the group consisting of alpelisib, cisplatin, oxaliplatin, ifosfamide, 5-fluorouracile, capecitabin, azacytidine, paclitaxel, docetaxel, vinorelbine, doxorubicin, irinotecan, cetuximab, erlotinib, and everolimus.
